Liraglutide therapy in obese people with type 2 diabetes - Experience of a weight management centre

European Journal of Internal Medicine

Volumn 25, Issue 3, 2014, Pages

  Elkhenini, Hanaa ^a,b   New, John P ^a,b   Summers, Lucinda K M ^a,b   Syed, Akheel A ^a,b  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Glucagon like peptide 1 receptor agonists; Obesity; Weight loss

Indexed keywords

CHOLESTEROL; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ARTHRALGIA; BACKACHE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHRONIC PAIN; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DEPRESSION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN TREATMENT; LETTER; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ADULT; AGED; ANALOGS AND DERIVATIVES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; WEIGHT LOSS; YOUNG ADULT;

EID: 84896391002     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.12.009     Document Type: Letter

References (10)

1. T. Vilsboll, M. Christensen, A.E. Junker, F.K. Knop, and L.L. Gluud Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 d7771
2. NICE Technology appraisals TA203. Liraglutide for the treatment of type 2 diabetes mellitus 2010 National Institute for Health and Care Excellence London [Available from www.nice.org.uk/guidance/TA203 ]
3. J.B. McGill Insights from the Liraglutide Clinical Development Program - the Liraglutide Effect and Action in Diabetes (LEAD) studies Postgrad Med 121 2009 16 25
4. Y. Seino, M.F. Rasmussen, M. Zdravkovic, and K. Kaku Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes Diabetes Res Clin Pract 81 2008 161 168
5. A. Astrup, S. Rossner, L. Van Gaal, A. Rissanen, L. Niskanen, and M. Al Hakim et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
6. B. Dhesi, H. Chauhan, and A. Basu Audit of clinical practice in the use of incretin mimetic agents for the management of patients with type 2 diabetes Pract Diabetes 30 2013 159 162
7. N. Kaimal, J. Schofield, A. Zaki, R. Patel, M. Sharma, and E. McCourt et al. Effects of exenatide in poorly controlled type 2 diabetes QJM 105 2012 321 326
8. L. Wessels, S. Keigan, S.V. O'Brien, and K.J. Hardy What proportion of patients fail NICE criteria for continuing GLP-1 treatment beyond six months, and why? Pract Diabetes 30 2013 196 198
9. B. Ryder, and K. Thong Findings from the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits J. Vora, Hot topics in diabetes 5 ed. 2012 Synergy London 49 61 [Available from www.diabetologists-abcd.org.uk/GLP1-Audits/ABCD-Hot-Topics-2012.pdf ]
10. R.E. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, and S. Filetti et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 2010 1447 1456